Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- Mar 10
- 1 min read
Updated: Mar 11
09/03/2026
Pfizer announced Phase 2 results of tilrekimig in AD (Ref)
Pfizer announced positive topline results from its Phase 2 study that evaluated tilrekimig (PF-07275315; trispecific antibody targets Il-4, IL-13 and TSLP) for the treatment of adult patients with moderate to severe atopic dermatitis (AD)
The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 compared to placebo
Tilrekimig was well-tolerated with a favorable safety profile
Based on encouraging results, the company planned to accelerate tilrekimig to Phase 3 development, with a pivotal study in AD on track to start this year
Vertex announced Phase 3 results of Povetacicept in IgA Nephropathy (Ref)
Vertex Pharmaceuticals announced positive interim analysis results from its Phase 3 RAINIER/ NCT06564142 study, which evaluated povetacicept (a BAFF and APRIL inhibitor) for the treatment of adult patients with immunoglobulin A nephropathy (IgAN)
The trial met its primary and secondary endpoints:
Primary endpoints: Patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour UPCR and achieved a statistically significant and clinically meaningful 49.8% reduction in UPCR versus placebo (P<0.0001)
Povetacicept was generally safe and well tolerated, and the majority of adverse events were mild to moderate
Vertex panned to complete Biologics License Application (BLA) by the end of March for potential US accelerated approval
